Ahmadabad. One of India’s fastest growing homegrown research-oriented pharmaceutical companies, Gujarat-based Asprius Lifesciences, has achieved a milestone in the treatment of Diabetic Neuropathy, a condition that causes nerve damage in peripheral areas of the body, leading to symptoms like weakness, numbness and acute pain in hands and feet. With astute focus on evidence-based medicines, extensive research and scientific formulations, Asprius Lifesciences has come up with a Fixed-Dose Combination (FDC) that is expected to treat peripheral neuropathy, a common condition with which over 2% of the global population deals currently.
While confirming that a patent for the FDC has already been filed, Vishal Zinzuwadia, Chairman & MD – Asprius Lifesciences, said, “Working on an innovation-based proposition, we have relentlessly been developing several groundbreaking pharmaceutical products in our bid to empower the medical fraternity and enhance patient treatment, especially when conventional therapies are ineffective. By actively addressing medical conditions that increase the risk of developing neuropathy and introducing neuro-protective medications, the company aims to support early neuronal regeneration and minimize the impact of the condition.”
The FDC development is spearheaded by the company’s medical director and renowned inventor Dr Sanjay Agrawal, who holds patents for nearly 42 other formulations. Elaborating on the need of immediately addressing the Diabetic Neuropathy scenario in the country, Dr Agrawal pointed that “India has a high prevalence of diabetes, with an estimated 77 million adults living with the disease, projected to rise to 101.2 million by 2030. In fact type 2 diabetes accounts for about 90-95% of all cases in India, and is often associated with lifestyle factors such as poor diet, sedentary lifestyle, and obesity. It is high time we addressed this prevelant condition, especially as Diabetic Neuropathy can damage specific subdivision of the nervous system.”
The Asprius Lifesciences Ahmadabad-based company is going to apply few more patents shortly.
